Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 34

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 34
---
 could have a material adverse impact on our liquidity, business, financial condition and results of
operations.

<div align='center'>25</div>

Certain of our directors, director nominees and/or officers may have interests that compete with ours and our shareholders.

Certain of our directors
currently own, operate and manage other entities, which may have similar or different objectives than ours. Such activities could detract
from the time these people have to allocate to our affairs. The terms of such agreements may not be as favorable to us as those that
could be obtained from a third party. Moreover, certain of our directors and officers are affiliated with our current shareholders, and
may have different interests than other shareholders. For additional information regarding related party transactions and potential conflicts
of interest, see “Certain Relationships and Related Party Transactions.” Under the Israeli Companies Law, 5759-1999, or the
Companies Law, office holders must promptly disclose to us any direct or indirect personal interest that he or she may have and all related
material information or documents known to him or her relating to any existing or proposed transaction by us. See “Fiduciary Duties
and Approval of Specified Related Party Transactions and Compensation Under Israeli Law—Disclosure of Personal Interests of an
Office Holder and Approval of Certain Transactions.” In addition, on the closing of this offering, we will adopt a code of ethics
and conduct that will require our employees, officers and directors to disclose any situation that reasonably would be expected to give
rise to a conflict of interest.

Our management team has limited experience managing a public company.

Most members of our management
team have limited experience managing a publicly traded company, interacting with public company investors and complying with the increasingly
complex laws pertaining to public companies in the United States. Our management team may not successfully or efficiently manage our
transition to being a public company subject to significant regulatory oversight and reporting obligations under the U.S. federal securities
laws and the continuous scrutiny of securities analysts and investors. These new obligations and constituents will require significant
attention from our senior management and could divert their attention away from the day-to-day management of our business, which could
adversely affect our business, financial condition, results of operations and prospects.

Any resurgence of the COVID-19 pandemic could adversely affect our business, financial condition and results of operations.

Public
health epidemics or outbreaks could adversely impact our business. In late 2019, a novel strain of COVID-19, also known as coronavirus,
was reported in Wuhan